[4,5-dimethoxy-2-(1-methyl-2-phenyl-ethyl)-phenyl]-(2,4-dimethoxy-pyrimidin-5-yl)-methanol | 865305-03-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: [4,5-dimethoxy-2-(1-methyl-2-phenyl-ethyl)-phenyl]-(2,4-dimethoxy-pyrimidin-5-yl)-methanol
• 英文别名: [4,5-dimethoxy-2-(1-phenylpropan-2-yl)phenyl]-(2,4-dimethoxypyrimidin-5-yl)methanol
• CAS: 865305-03-9
• 化学式: C₂₄H₂₈N₂O₅
• 分子量: 424.497
• InChiKey: HPHLHYJFFVPDCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  82.9
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  [4,5-dimethoxy-2-(1-methyl-2-phenyl-ethyl)-phenyl]-(2,4-dimethoxy-pyrimidin-5-yl)-methanol 在 二氧化锰 水 、 ethyl acetate n-hexane 作用下， 以 甲苯 为溶剂， 反应 1.0h， 以afforded [4,5-dimethoxy-2-(1-methyl-2-phenyl-ethyl)-phenyl]-(2,4-dimethoxy-pyrimidin-5-yl)-methanone (0.258 g, 62%) as a clear oil的产率得到[4,5-dimethoxy-2-(1-methyl-2-phenyl-ethyl)-phenyl]-(2,4-dimethoxy-pyrimidin-5-yl)-methanone
  参考文献：
  名称：

  Diaminopyrimidines as P2X3 and P2X2/3 antagonists

  摘要：

  本发明涉及一种用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病的化合物和方法，所述方法包括向需要治疗的受体中注射有效量的公式（I）的化合物或其药学上可接受的盐、溶剂或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。

  公开号：

  US07858632B2
• 作为产物：
  描述：

  2,4-二甲氧基嘧啶 、 4,5-dimethoxy-2-(1-methyl-2-phenyl-ethyl)-benzaldehyde 在 2,2,6,6-四甲基哌啶 、 正丁基锂 、 氯化铵 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.42h， 以52%的产率得到[4,5-dimethoxy-2-(1-methyl-2-phenyl-ethyl)-phenyl]-(2,4-dimethoxy-pyrimidin-5-yl)-methanol
  参考文献：
  名称：

  Diaminopyrimidines as P2X3 and P2X2/3 antagonists

  摘要：

  用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病的治疗化合物和方法，该方法包括向有需要的受试者施用有效量的式I化合物：或其药学上可接受的盐、溶剂化物或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。

  公开号：

  US20050209260A1

文献信息

• Diaminopyrimidines as P2X3 and P2X2/3 antagonists
  申请人：Broka Allen Chris

  公开号：US20050209260A1

  公开（公告）日：2005-09-22

  Compounds and methods for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病的治疗化合物和方法，该方法包括向有需要的受试者施用有效量的式I化合物：或其药学上可接受的盐、溶剂化物或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• [EN] DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS<br/>[FR] DIAMINOPYRIMIDINES UTILISEES EN TANT QU'ANTAGONISTES DE P2X3 ET P2X2/3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005095359A1

  公开（公告）日：2005-10-13

  Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonists, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

  本发明涉及用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病的化合物和方法，所述方法包括向需要治疗的受体中给予公式（I）的化合物或其药学上可接受的盐、溶剂或前药的有效量，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
  申请人：Broka Chris Allen

  公开号：US20110077242A1

  公开（公告）日：2011-03-31

  Compounds and methods for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  本发明涉及化合物和方法，用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病，其中所述方法包括向需要该治疗的受体中施用化合物I式的有效量，或其药学上可接受的盐、溶剂或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES
  申请人：Broka Chris Allen

  公开号：US20120122859A1

  公开（公告）日：2012-05-17

  Methods for treating respiratory and gastrointestinal diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  治疗由P2X3和/或P2X2/3受体拮抗剂介导的呼吸道和胃肠道疾病的方法，包括向需要治疗的个体施用式(I)的化合物的有效量或其药学上可接受的盐，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如此定义。
• Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseases
  申请人：Broka Chris Allen

  公开号：US08524725B2

  公开（公告）日：2013-09-03

  Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

  治疗由P2X3和/或P2X2/3受体拮抗剂介导的呼吸和胃肠疾病的方法，包括向需要该方法的受体中投与化合物的有效量，该化合物的公式为（I）或其药学上可接受的盐，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8的定义如本文所述。